This study evaluated an obstetrical program using rapid HIV testing for the prevention of mother-to-child HIV transmission (MTCT) in Baja California, Mexico. Between 2003 and 2005, 45 women in labor and 17 prenatal care women were HIV infected. Among labor patients, 14 (31%) delivered by cesarean section compared with 17 (100%) prenatal care patients (P < .001). Intravenous maternal zidovudine (ZDV) and infant oral ZDV were more frequently administered in prenatal care compared to labor patients: 94% versus 33% (P < .001) and 100% versus 79% (P < .001), respectively. All prenatal care women received combination therapy. All 10 HIV-infected infants were in the labor group, resulting in a MTCT rate of 23% (95% confidence interval [CI] 9.5-34.8) compared to 0% (95% CI 0-1.8; P < .001) among the prenatal care group. Five (50%) of the HIV-infected infants had an AIDS diagnosis and 2 (20%) died within 18 months of birth. Women diagnosed during labor had a high HIV MTCT and poor postnatal outcome.
Introduction
During 2007, 290 000 children died of HIV/AIDS and 410 000 were newly infected worldwide. 1 The great majority of HIV infections in children occur in developing countries as a consequence of mother-to-child transmission (MTCT) that to a great extent is preventable if antiretroviral therapy (ART) could be administered to the pregnant woman and her newborn infant and formula feeding is feasible. Other approaches including the use of cesarean section before the onset of labor or ruptured membranes, intrapartum maternal and neonatal chemoprophylaxis, or ART during breastfeeding can help decrease MTCT when optimal intervention is unavailable. [2] [3] [4] [5] [6] AIDS is a major health concern along the US-Mexico border. Mexico ranks third in the Americas for AIDS cases with 124 505 cases accumulated as of November 2008. 7 According to CONASIDA (Mexican National AIDS Council), Baja California, including Tijuana, has the second highest rate of AIDS in Mexico with 179 cases per 100 000. This is 55% higher than the Mexican national average and second only to the Federal District. 7 The Tijuana General Hospital serves uninsured persons who are economically disadvantaged. The obstetrics department has an average of 489 deliveries per month of which only 26% have more than 2 prenatal visits. In addition, prenatal HIV testing and treatment to prevent maternal-fetal transmission was not fully implemented until 2003. 8, 9 During 2003 and 2004, we conducted a study to examine the acceptance of HIV counseling and rapid testing using Determine 1 HIV-1/2 during pregnancy and at delivery. The acceptance rate of rapid HIV testing during prenatal care and at delivery was *95%. The HIV seroprevalence was significantly higher among women screened during labor; 1.12% compared to 0.33% for those seeking prenatal care. 9 In industrialized countries, HIV MTCT in the absence of intervention other than formula feeding is 25%. 2 In developing countries where breastfeeding is common, the MTCT increases to 40%. 10 The purpose of this study, as a natural extension of our previous study, 9 was to characterize the obstetrical and medical management of HIV-infected women, to evaluate the MTCT rate, and to assess morbidity associated with HIV among a cohort of HIV-infected pregnant women who were diagnosed during prenatal care or at delivery at Tijuana General Hospital, Mexico. HIV diagnosis was made by means of the rapid HIV antibody test Determine 1 HIV-1/2 (Abbott Diagnostics, North Chicago, Illinois). Women enrolled in the prenatal care clinics with a positive rapid test result were informed of the preliminary nature of the test, and a confirmatory Western blot (Focus Technologies, Cipres, California) was performed. Women were enrolled in the labor and delivery unit if their HIV status was unknown, regardless of prenatal care visits. Women in the labor and delivery unit whose Determine HIV-1/2 test was positive were given appropriate counseling, serum was sent for a confirmatory HIV Western blot, and intravenous zidovudine (ZDV) was administered. Infants born to HIV-infected women diagnosed during prenatal care or at the labor and delivery unit were given oral ZDV for 6 weeks. Demographic data, clinical data, US Centers for Disease Control and Prevention (CDC) clinical classification, morbidity data, and delivery information were prospectively collected using a standardized form. Women enrolled during prenatal care were prescribed combination ART as soon as HIV infection was confirmed and received ZDV, lamivudine (3TC), and nelfinavir (NFV) as a prophylactic regimen to prevent MTCT. All HIV-infected pregnant women had blood drawn for CD4 T-cell count and plasma HIV-1 RNA viral load (VL) prior to ART, and for women in prenatal care, both tests were repeated at delivery. HIV-infected pregnant women were advised not to breastfeed their infants and to use formula feeding.
Methods
Infants exposed to HIV were followed at the Pediatric clinic at Tijuana General Hospital. Exposed infants had blood samples collected at birth, 2, and 6 months for HIV DNA polymerase chain reaction (PCR) performed at the UCSD Center for AIDS Research Virology Core Laboratory. Infants diagnosed with HIV infection were followed at the Pediatric HIV clinic and monitored for morbidity associated with HIV. Antiretroviral therapy was prescribed according to the Mexican guidelines. 11 Statistical analyses were performed using the Student t test to compare differences between sample means using GB-STAT version 6.5 (Dynamic Microsystems, Inc, Silver Spring, Maryland). Statistical significance was designated at P < .05. All P values were 2-tailed.
Results
There were a total of 62 HIV-infected pregnant women who delivered during the study period; 45 women were diagnosed at the labor and delivery unit and 17 were diagnosed at the prenatal care clinic.
The mean age was 25.5 years (SD + 6.3) and 26.6 years (SD + 5) for women diagnosed during prenatal care and at delivery, respectively. The mean gravidity did not differ and was 3.2 (SD + 2.6) and 3.8 (SD + 2.2) pregnancies for women diagnosed during prenatal care and at delivery, respectively. The number of prenatal care visits at HIV diagnosis was more frequent in the prenatal care group compared to the labor group, 4.9 (SD + 0.5) versus 1.5 visits (SD + 2.2), respectively (P < .0001; Table 1 ). Risk factors for HIV acquisition including injection drug use, methamphetamine use, higher number of sexual partners, commercial sex, history of jail time, and homelessness were more frequently present in the labor group. However, no risk factors could be elicited among 41% and 18% of women in the prenatal care and labor groups, respectively (P < .001; Table 2 ). All women had a CDC clinical classification A at diagnosis and were asymptomatic. In terms of the CDC immunologic classification, 8 (13%) women were category 1, 22 (36%) women were category 2, and 4 (6%) women were category 3. In 28 (45%) women, CD4 count was not available at diagnosis. For those with specimens available at diagnosis, the mean CD4 count and HIV RNA PCR did not differ among women diagnosed in prenatal care or at delivery ( Table 1 ). The mean gestational age at delivery did not differ between women diagnosed during prenatal care or at delivery: 38.7 (SD + 0.75) and 38.3 weeks (SD + 3; P ¼ NS), respectively. Interventions to reduce HIV MTCT were more likely to occur in the prenatal care group, and risk factors associated with HIV MTCT were more likely to occur in the labor and delivery group (Table 3) . The mean gestational age at HIV diagnosis was 21 weeks (SD + 9.4) among women diagnosed at the prenatal care clinic. All 17 women initiated triple combination therapy with ZDV, 3TC, and NFV; 14 women tolerated the regimen well and continued with it until delivery; 3 women did not tolerate the regimen and received ZDV and 3TC only until delivery. Sixteen (94%) received intravenous ZDV intrapartum and all 17 newborns received oral ZDV. Among these infants, there were no HIV infections. Fifteen infants had persistently negative HIV DNA PCR and negative HIV enzyme immunoassay (EIA) after 18 months. Two infants had a negative HIV DNA PCR at birth but were lost to follow-up.
Among the women diagnosed in labor, 14 (31%) patients received intravenous ZDV. There were 42 live births and 3 stillbirths, due to prematurity among women without prenatal care (Table 4 ). Thirty-three (79%) infants received oral ZDV for 6 weeks. Maternal complications at delivery occurred in 5 patients, 4 developed chorioamnionitis and 1 had syphilis. Tuberculosis was an important maternal complication occurring within the 24 months of follow-up (Table 5 ). Two women developed tuberculous meningitis, 1 of whom died and the other survived with neurologic sequelae. Three additional women developed pulmonary tuberculosis, 2 of whom died ( Table 5 ). Eighteen infants had persistently negative HIV DNA PCR. An additional 10 had negative HIV DNA PCR at birth but were lost to follow-up, and 2 had no HIV DNA PCR performed. Ten of 43 infants with at least 1 HIV DNA PCR performed were identified as HIV infected, giving an MTCT rate of at least 23% (95% CI 9.5-34.8) compared to no transmission in the prenatal group (95% CI 0-1.8; P < .001; Figure 1 ). Among the 10 infected infants, 3 (30%) had a positive HIV DNA PCR at birth indicating intrauterine infection. Infant morbidity and mortality was high. Three of the infants were diagnosed with tuberculosis; one each with meningitis, pulmonary, or miliary tuberculosis. All 3 children were the offspring of women diagnosed with tuberculosis. Two children died, 1 due to pneumonia and the other due to tuberculous meningitis ( Table 5 ).
Discussion
This study describes a cohort of pregnant women from a single institution in Mexico identified as HIV infected by means of rapid HIV testing during pregnancy or at delivery. To our knowledge, this is the largest report of the obstetrical and medical management of HIV-infected pregnant women in the era of combination ART in Mexico. The majority of patients was identified in labor (73%) and was less likely to have adequate prenatal care. Risk factors for HIV acquisition were more frequent among women diagnosed during labor. These women were less likely to have adequate prenatal care and frequently their only encounter with the health system was at delivery. It is important to note that no risk factor other than having sex with their spouse was identified in 41% of women in the prenatal group and 18% of women in the labor group, emphasizing the need for HIV testing in pregnancy regardless of the perceived absence of HIV-associated risk factors. Two reports from Mexico City prior to the era of combination ART and other reports from Latin America found heterosexual transmission as the most frequent HIV-associated risk factor among pregnant women. [12] [13] [14] [15] All women identified during prenatal care delivered by scheduled cesarean section, 53% in the absence of labor in contrast to 4% of women identified at the labor unit. Previous studies in Mexico have shown lower rates of cesarean section (25%) in women enrolled during pregnancy without specification of onset of labor. 12, 13 Studies in Latin America have shown lower rates of elective cesarean section but 1 study in Argentina showed an increase in the use of elective cesarean section from 19% to 54% between 1993 and 2000. [14] [15] [16] Recently, a National Institute of Child Health and Human Development (NICHD) Perinatal Study conducted in Latin America found a similarly high cesarean section rate in their Mexican site at 61% among HIV-infected women enrolled during prenatal care. 17 In addition, the same study found a similar rate of preterm delivery at 9% as in our current study. 17 Combination ART during pregnancy and low VL at delivery are both associated with a decrease in HIV MTCT. 5 All women diagnosed during prenatal care were treated with combination ART and their mean VL at delivery decreased significantly with no HIV transmissions reported among this group. A previous study from Mexico City, prior to the advent of combination ART, found a high MTCT rate among HIV-infected pregnant women followed for 18 months postdelivery with a transmission rate between 33% and 52%. 12 In agreement with our study, the NICHD-sponsored Latin American study conducted in the era of combination ART found a good VL reduction at delivery among HIV-infected pregnant women enrolled during prenatal care and like our study had a very low MTCT rate of 0.91%. 17 There are no published studies evaluating HIV MTCT rate when women are diagnosed with HIV infection at delivery in Mexico. Our transmission rate was 23%, which is higher than that reported for women identified as HIV infected at delivery in the United States. 3 An explanation for our high transmission rate in the labor group could be related to the poor compliance with intrapartum ZDV and with oral ZDV in the newborn. In addition, women diagnosed during labor had more risk factors for HIV acquisition, in particular drug use, and more risk factors for HIV MTCT, such as vaginal delivery, absence of ART, prolonged rupture of membranes, lower birth weight, and higher HIV VL. 5, 18 We observed a high maternal and neonatal morbidity and mortality in the labor group. Among the 10 HIV-infected infants, 5 (50%) developed AIDS-defining conditions and 2 (20%) died due to pneumonia and tuberculous meningitis. In addition, maternal morbidity and mortality due to tuberculosis was high during the follow-up period. There are no comparable Mexican studies evaluating maternal and infant morbidity and mortality in the era of combination ART.
A limitation of our study was the poor follow-up of the women and children during the postpartum period that prevented us from capturing important information on postnatal compliance with oral ZDV in HIV-exposed children.
In summary, we observed a high rate of HIV MTCT in the labor group at Tijuana General Hospital. In addition, we found a high maternal morbidity and mortality associated with HIV among the labor group in contrast to the successful outcomes among women diagnosed during prenatal care. These findings further emphasize the need to expand the access to prenatal care and to develop comprehensive prenatal HIV screening program in Mexico to reduce the number of missed opportunities to prevent HIV MTCT.
